Citations (189)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (25)
Guido Mioso, Laura Gnesotto, Irene Russo, Stefano Piaserico & Mauro Alaibac. (2023) Exacerbation of psoriasis induced by lenalidomide in a patient with multiple myeloma. Journal of Dermatological Treatment 34:1.
Read now
Read now
Balaji Wamanrao Matore, Partha Pratim Roy & Jagadish Singh. (2023) Discovery of novel VEGFR2-TK inhibitors by phthalimide pharmacophore based virtual screening, molecular docking, MD simulation and DFT. Journal of Biomolecular Structure and Dynamics 41:22, pages 13056-13077.
Read now
Read now
Yilin Liu, Yuming Song, Yingju Xu, Meixu Jiang & Haibin Lu. (2022) Design, synthesis, and biological evaluation of a novel series of 2-(2,6-dioxopiperidin-3-yl)isoquinoline-1,3(2H,4H)-dione derivatives as cereblon modulators. Journal of Enzyme Inhibition and Medicinal Chemistry 37:1, pages 1715-1723.
Read now
Read now
Huihan Wang, Hua Shi, Xiaowei He & Aijun Liao. (2021) Downregulation of Chemokine CCL20 Involved in Myeloma Cells Resistant to Elotuzumab and Lenalidomide. OncoTargets and Therapy 14, pages 2789-2795.
Read now
Read now
Evans D. Pope, Laura Cordes, Jiong Shi, Zoltan Mari, Boris Decourt & Marwan Noel Sabbagh. (2021) Dementia with Lewy bodies: emerging drug targets and therapeutics. Expert Opinion on Investigational Drugs 30:6, pages 603-609.
Read now
Read now
Michel Delforge, Sophie Vlayen & Nicolas Kint. (2021) Immunomodulators in newly diagnosed multiple myeloma: current and future concepts. Expert Review of Hematology 14:4, pages 365-376.
Read now
Read now
Boris Decourt, Jeffrey Wilson, Aaron Ritter, Christopher Dardis, Frank P DiFilippo, Xiaowei Zhuang, Dietmar Cordes, Garam Lee, Nadia D Fulkerson, Tessa St Rose, Katurah Hartley & Marwan N Sabbagh. (2020) MCLENA-1: A Phase II Clinical Trial for the Assessment of Safety, Tolerability, and Efficacy of Lenalidomide in Patients with Mild Cognitive Impairment Due to Alzheimer’s Disease. Open Access Journal of Clinical Trials 12, pages 1-13.
Read now
Read now
Christine I. Chen, Harminder Paul, Susi Snitzler, Sumeet Kakar, Lisa W. Le, Ellen N. Wei, Anthea Lau, James B. Johnston, Spencer B. Gibson, Michelle Queau, David Spaner, Danielle Croucher, Barbara Sherry & Suzanne Trudel. (2019) A phase 2 study of lenalidomide and dexamethasone in previously untreated patients with chronic lymphocytic leukemia (CLL). Leukemia & Lymphoma 60:4, pages 980-989.
Read now
Read now
Jan-Paul Bohn, Wolfgang Willenbacher, Ines Peschel, Herbert Oberacher & Michael Steurer. (2019) Second-generation immunomodulatory drugs in leptomeningeal myeloma. Leukemia & Lymphoma 60:2, pages 550-552.
Read now
Read now
Xiaozhong Qian, Meletios A. Dimopoulos, Michael Amatangelo, Chad Bjorklund, Fadi Towfic, Erin Flynt, Katja C. Weisel, Enrique M. Ocio, Xin Yu, Teresa Peluso, Lars Sternas, Mohamed Zaki, Philippe Moreau & Anjan Thakurta. (2019) Cereblon gene expression and correlation with clinical outcomes in patients with relapsed/refractory multiple myeloma treated with pomalidomide: an analysis of STRATUS. Leukemia & Lymphoma 60:2, pages 462-470.
Read now
Read now
Brandon Kremer, Donald E. Tsai, Fotini Debonera, Patti L. Cohen & Stephen J. Schuster. (2018) Spontaneous remission of acute myeloid leukemia after discontinuation of lenalidomide. Leukemia & Lymphoma 59:3, pages 743-745.
Read now
Read now
Hannah E. Feinman, Douglas K. Price & William D. Figg. (2017) Piecing the puzzle together: Docetaxel cycles and current considerations in the treatment of metastatic castration-resistant prostate cancer. Cancer Biology & Therapy 18:4, pages 203-204.
Read now
Read now
Samah Alimam & Claire Harrison. (2016) Is there a role for pomalidomide in the treatment of myelofibrosis?. Expert Opinion on Orphan Drugs 4:5, pages 501-509.
Read now
Read now
J. R. Jones, C. Pawlyn, F. E. Davies & G. J. Morgan. (2016) The safety of pomalidomide for the treatment of multiple myeloma. Expert Opinion on Drug Safety 15:4, pages 535-547.
Read now
Read now
Junya Kuroda, Tsutomu Kobayashi & Masafumi Taniwaki. (2015) Prognostic indicators of lenalidomide for multiple myeloma: consensus and controversy. Expert Review of Anticancer Therapy 15:7, pages 787-804.
Read now
Read now
Minal Surati, Kelly Valla, Katherine Sanvidge Shah, Elyse Hall Panjic & Sagar Lonial. (2015) Panobinostat for the treatment of multiple myeloma. Expert Opinion on Orphan Drugs 3:2, pages 229-238.
Read now
Read now
Edward N Libby, Pamela S Becker, Nicholas Burwick, Damian J Green, Leona Holmberg & William Ira Bensinger. (2015) Panobinostat: a review of trial results and future prospects in multiple myeloma. Expert Review of Hematology 8:1, pages 9-18.
Read now
Read now
Sylwia Łopuch, Paweł Kawalec & Natalia Wiśniewska. (2015) Effectiveness of targeted therapy as monotherapy or combined therapy in patients with relapsed or refractory multiple myeloma: A systematic review and meta-analysis. Hematology 20:1, pages 1-10.
Read now
Read now
Guillemette Fouquet, Claire Bories, Stéphanie Guidez, Loïc Renaud, Charles Herbaux, Sahir Javed, Thierry Facon & Xavier Leleu. (2014) Pomalidomide for multiple myeloma. Expert Review of Hematology 7:6, pages 719-731.
Read now
Read now
Danyu Sun & Mitchell R Smith. (2014) Bortezomib for the treatment of mantle cell lymphoma. Expert Opinion on Orphan Drugs 2:11, pages 1233-1241.
Read now
Read now
Anna Guidetti, Claudia Paba Prada, Jacob P Laubach, Cindy Varga, Michelle E Maglio, Mary McKenney, Deborah Doss, Robert L Schlossman, Constantine Mitsiades, Teru Hideshima, Güllü T Görgün, Irene M Ghobrial, Noopur Raje, Nikhil Munshi, Kenneth C Anderson & Paul G Richardson. (2014)
Pomalidomide for the treatment of relapsed and refractory multiple myeloma. Expert Opinion on Orphan Drugs 2:10, pages 1089-1108.
Read now
Read now
Marc Fakhoury, Rebecca Negrulj, Armin Mooranian & Hani Al-Salami. (2014) Inflammatory bowel disease: clinical aspects and treatments. Journal of Inflammation Research 7, pages 113-120.
Read now
Read now
Evangelos Terpos, Nikolaos Kanellias, Dimitrios Christoulas, Efstathios Kastritis & Meletios A Dimopoulos. (2013) Pomalidomide: a novel drug to treat relapsed and refractory multiple myeloma. OncoTargets and Therapy 6, pages 531-538.
Read now
Read now
Francesca Gay, Roberto Mina, Rossella Troia & Sara Bringhen. (2013) Pharmacokinetic evaluation of pomalidomide for the treatment of myeloma. Expert Opinion on Drug Metabolism & Toxicology 9:11, pages 1517-1527.
Read now
Read now
David R. Janero. Current strategic trends in drug discovery: the present as prologue. Expert Opinion on Drug Discovery 0:0, pages 1-13.
Read now
Read now
Articles from other publishers (164)
Maged Mohammed Saleh Al Ward, Abdallah E. Abdallah, Mohamed F. Zayed, Rezk R. Ayyad & Mohamed Ayman El-Zahabi. (2024) Design, synthesis and biological evaluation of newly triazolo-quinoxaline based potential immunomodulatory anticancer molecules. Journal of Molecular Structure 1298, pages 137041.
Crossref
Crossref
Patrick M. Jedlowski & Jason P. DuPont. (2023)
Multiple myeloma, haematologic malignancy and immunosuppressant and immunomodulatory medications are associated with sebaceous carcinoma, a pharmacovigilance study of the
FDA
adverse event reporting system
. Journal of the European Academy of Dermatology and Venereology.
Crossref
Crossref
Bhaskar Basu, Satadeepa Kal, Subhajit Karmakar, Malini Basu & Mrinal K. Ghosh. (2023) E3 ubiquitin ligases in lung cancer: Emerging insights and therapeutic opportunities. Life Sciences, pages 122333.
Crossref
Crossref
Yan Zhuang, Chenyu Li, Hua Jiang, Lu Li, Yuanteng Zhang, Wei Yu & WeiJun Fu. (2023) Multi-omics investigation of the resistance mechanisms of pomalidomide in multiple myeloma. Frontiers in Oncology 13.
Crossref
Crossref
David G. Coffey, Francesco Maura, Edgar Gonzalez-Kozlova, J. Javier Diaz-Mejia, Ping Luo, Yong Zhang, Yuexin Xu, Edus H. Warren, Travis Dawson, Brian Lee, Hui Xie, Eric Smith, Amanda Ciardiello, Hearn J. Cho, Adeeb Rahman, Seunghee Kim-Schulze, Benjamin Diamond, Alexander Lesokhin, Dickran Kazandjian, Trevor J. Pugh, Damian J. Green, Sacha Gnjatic & Ola Landgren. (2023) Immunophenotypic correlates of sustained MRD negativity in patients with multiple myeloma. Nature Communications 14:1.
Crossref
Crossref
Hazem Elkady, Khaled El‐Adl, Helmy Sakr, Adel S. Abdelraheem, Sally I. Eissa & Mohamed Ayman El‐Zahabi. (2023) Novel promising benzoxazole/benzothiazole‐derived immunomodulatory agents: Design, synthesis, anticancer evaluation, and in silico ADMET analysis. Archiv der Pharmazie 356:9.
Crossref
Crossref
Can Zhao, Henian Wang, Wenhu Zhan, Xiaoqing Lv & Xiaodong Ma. (2023) Exploitation of Proximity-Mediated Effects in Drug Discovery: An Update of Recent Research Highlights in Perturbing Pathogenic Proteins and Correlated Issues. Journal of Medicinal Chemistry 66:15, pages 10122-10149.
Crossref
Crossref
Reda Mabrouk, Abdallah Abdallah, Hazem Mahdy, Samar El-Kalyoubi, Omar Kamal, Tamer Abdelghany, Mohamed Zayed, Heba Alshaeri, Moudi Alasmari & Mohamed El-Zahabi. (2023) Design, Synthesis, and Biological Evaluation of New Potential Unusual Modified Anticancer Immunomodulators for Possible Non-Teratogenic Quinazoline-Based Thalidomide Analogs. International Journal of Molecular Sciences 24:15, pages 12416.
Crossref
Crossref
Bin Yang & Xiangbing Qi. (2023) Research progress in small-molecule modulators of protein-protein interactions. Chinese Science Bulletin 68:23, pages 3005-3040.
Crossref
Crossref
Mahya Aghaee, Urszula Ledzewicz, Michael Robbins, Natalie Bezman, Hearn Jay Cho & Helen Moore. (2023) Determining optimal combination regimens for patients with multiple myeloma. European Journal of Pharmaceutical Sciences 187, pages 106492.
Crossref
Crossref
Janny V. Evenhuis, Andrew Oates, Naomi Hoyer, Allison C. Vilander, Douglass H. Thamm & Deanna R. Worley. (2023) A retrospective study of canine oral extramedullary plasmacytoma over a 15‐year period (July 2004–July 2019): Treatment, histologic parameters and clinical outcomes. Veterinary and Comparative Oncology 21:2, pages 302-314.
Crossref
Crossref
Abdallah E. Abdallah, Ibrahim H. Eissa, Ahmed B.M. Mehany, Helmy Sakr, Ahmed Atwa, Khaled El-Adl & Mohamed Ayman El-Zahabi. (2023) Immunomodulatory quinazoline-based thalidomide analogs: Design, synthesis, apoptosis and anticancer evaluations. Journal of Molecular Structure 1281, pages 135164.
Crossref
Crossref
Daniel Schaefer & Xinlai Cheng. (2023) Recent Advances in Covalent Drug Discovery. Pharmaceuticals 16:5, pages 663.
Crossref
Crossref
Katherine O. Kopp, Margaret E. Greer, Elliot J. Glotfelty, Shih-Chang Hsueh, David Tweedie, Dong Seok Kim, Marcella Reale, Neil Vargesson & Nigel H. Greig. (2023) A New Generation of IMiDs as Treatments for Neuroinflammatory and Neurodegenerative Disorders. Biomolecules 13:5, pages 747.
Crossref
Crossref
Ilaria Saltarella, Concetta Altamura, Carmen Campanale, Paola Laghetti, Angelo Vacca, Maria Antonia Frassanito & Jean-François Desaphy. (2023) Anti-Angiogenic Activity of Drugs in Multiple Myeloma. Cancers 15:7, pages 1990.
Crossref
Crossref
Ashwin Gollerkeri,Jared Gollob, and & Nello Mainolfi. 2023. Precision Cancer Therapies, Volume 1 ‐ Targeting Oncogenic Drivers and Signaling Pathways in Lymphoid Malignancies. Precision Cancer Therapies, Volume 1 ‐ Targeting Oncogenic Drivers and Signaling Pathways in Lymphoid Malignancies
372
379
.
Piotr Kulig, Sławomir Milczarek, Estera Bakinowska, Laura Szalewska, Bartłomiej Baumert & Bogusław Machaliński. (2023) Lenalidomide in Multiple Myeloma: Review of Resistance Mechanisms, Current Treatment Strategies and Future Perspectives. Cancers 15:3, pages 963.
Crossref
Crossref
Linyi Liu, Renhong Sun, Haixia Liu, Chaowei Ren, Yuedong Zhou, Xing Qiu, Ying Kong, Biao Jiang & Xiaobao Yang. (2023) Design, synthesis and biological evaluation of novel quinazolinone derivatives as CRBN E3 ligase modulators. European Journal of Medicinal Chemistry 247, pages 115016.
Crossref
Crossref
Kyung-Jin Kim, Jun-Bean Park, Seung-Pyo Lee, Hyung-Kwan Kim & Yong-Jin Kim. (2023) Thalidomide and a Dipeptidyl Peptidase 4 Inhibitor in a Rat Model of Experimental Autoimmune Myocarditis. Korean Circulation Journal 53:12, pages 795.
Crossref
Crossref
Murat Kaçmaz & Hamdi Oğuzman. (2023) The Leucine-Rich α2-Glycoprotein-1 Levels in Patients with Multiple Myeloma. Oncology Research and Treatment 46:10, pages 415-423.
Crossref
Crossref
Surya K. De. 2023. Medicines for Cancer. Medicines for Cancer
205
411
.
Anas Ramadan Kotb, Dina A. Bakhotmah, Abdallah E. Abdallah, Hazem Elkady, Mohammed S. Taghour, Ibrahim. H. Eissa & Mohamed Ayman El-Zahabi. (2022) Design, synthesis, and biological evaluation of novel bioactive thalidomide analogs as anticancer immunomodulatory agents. RSC Advances 12:52, pages 33525-33539.
Crossref
Crossref
Lucia Y. Chen & Sarah Gooding. (2022) Tumor and microenvironmental mechanisms of resistance to immunomodulatory drugs in multiple myeloma. Frontiers in Oncology 12.
Crossref
Crossref
Igor Radanovic, Naomi Klarenbeek, Robert Rissmann, Geert Jan Groeneveld, Emilie M. J. van Brummelen, Matthijs Moerland & Jacobus J. Bosch. (2022) Integration of healthy volunteers in early phase clinical trials with immuno-oncological compounds. Frontiers in Oncology 12.
Crossref
Crossref
Kathryn Lurain, Robert Yarchoan & Ramya Ramaswami. (2022) Immunotherapy for KSHV-associated diseases. Current Opinion in Virology 55, pages 101249.
Crossref
Crossref
Guangzhong Yang, Chuanying Geng, Yuan Jian, Huixing Zhou & Wenming Chen. (2022) Triplet RVd Induction for Transplant-Eligible Newly Diagnosed Multiple Myeloma: A Systematic Review and Meta-Analysis. Advances in Therapy 39:8, pages 3799-3834.
Crossref
Crossref
Grant Sprow, Joshua Dan, Joseph F. Merola & Victoria P. Werth. (2022) Emerging Therapies in Cutaneous Lupus Erythematosus. Frontiers in Medicine 9.
Crossref
Crossref
Philip Vlummens, Stefaan Verhulst, Kim De Veirman, Anke Maes, Eline Menu, Jérome Moreaux, Hugues De Boussac, Nicolas Robert, Elke De Bruyne, Dirk Hose, Fritz Offner, Karin Vanderkerken & Ken Maes. (2022) Inhibition of the Protein Arginine Methyltransferase PRMT5 in High-Risk Multiple Myeloma as a Novel Treatment Approach. Frontiers in Cell and Developmental Biology 10.
Crossref
Crossref
Harish Kumar, Suman Mazumder, Neeraj Sharma, Sayak Chakravarti, Mark D. Long, Nathalie Meurice, Joachim Petit, Song Liu, Marta Chesi, Sabyasachi Sanyal, A. Keith Stewart, Shaji Kumar, Leif Bergsagel, S. Vincent Rajkumar, Linda B. Baughn, Brian G. Van Ness & Amit Kumar Mitra. (2022) Single-Cell Proteomics and Tumor RNAseq Identify Novel Pathways Associated With Clofazimine Sensitivity in PI- and IMiD- Resistant Myeloma, and Putative Stem-Like Cells. Frontiers in Oncology 12.
Crossref
Crossref
Ramya Ramaswami, Mark N. Polizzotto, Kathryn Lurain, Kathleen M. Wyvill, Anaida Widell, Jomy George, Priscila Goncalves, Seth M. Steinberg, Denise Whitby, Thomas S. Uldrick & Robert Yarchoan. (2022) Safety, Activity, and Long-term Outcomes of Pomalidomide in the Treatment of Kaposi Sarcoma among Individuals with or without HIV Infection. Clinical Cancer Research 28:5, pages 840-850.
Crossref
Crossref
Bruno Dutra Arbo, Lucia Emanueli Schimith, Michele Goulart dos Santos & Mariana Appel Hort. (2022) Repositioning and development of new treatments for neurodegenerative diseases: Focus on neuroinflammation. European Journal of Pharmacology 919, pages 174800.
Crossref
Crossref
Dia Advani, Sudhanshu Sharma, Smita Kumari, Rashmi K. Ambasta & Pravir Kumar. (2022) Precision Oncology, Signaling, and Anticancer Agents in Cancer Therapeutics. Anti-Cancer Agents in Medicinal Chemistry 22:3, pages 433-468.
Crossref
Crossref
Maria Cecilia V.A. de Oliveira, Douglas C.F. Viana, Anderson A. Silva, Michelly C. Pereira, Filipe S. Duarte, Maira G.R. Pitta, Ivan R. Pitta & Marina G.R. Pitta. (2022) Synthesis of novel thiazolidinic-phthalimide derivatives evaluated as new multi-target antiepileptic agents. Bioorganic Chemistry 119, pages 105548.
Crossref
Crossref
Srijit Das, Norsham Juliana, Noor Anisah Abu Yazit, Sahar Azmani & Izuddin Fahmy Abu. (2022) Multiple Myeloma: Challenges Encountered and Future Options for Better Treatment. International Journal of Molecular Sciences 23:3, pages 1649.
Crossref
Crossref
Perpétua do Socorro Silva Costa, Miriãn Ferrão Maciel-Fiuza, Thayne Woycinck Kowalski, Lucas Rosa Fraga, Mariléa Furtado Feira, Luís Marcelo Aranha Camargo, Daniele Iop de Oliveira Caldoncelli, Maria Irismar da Silva Silveira, Lavínia Schuler-Faccini & Fernanda Sales Luiz Vianna. (2022) Evaluation of the influence of genetic variants in Cereblon gene on the response to the treatment of erythema nodosum leprosum with thalidomide. Memórias do Instituto Oswaldo Cruz 117.
Crossref
Crossref
Despina Fotiou, Maria Gavriatopoulou, Evangelos Terpos & Meletios A. Dimopoulos. (2022) Pomalidomide- and dexamethasone-based regimens in the treatment of refractory/relapsed multiple myeloma. Therapeutic Advances in Hematology 13, pages 204062072210900.
Crossref
Crossref
Christoph Ritter, Susen Burock & Ulrich Keilholz. 2020. Kompendium Internistische Onkologie. Kompendium Internistische Onkologie
1
14
.
Ramya Ramaswami, Kathryn Lurain & Robert Yarchoan. (2021) Oncologic Treatment of HIV-Associated Kaposi Sarcoma 40 Years on. Journal of Clinical Oncology.
Crossref
Crossref
Sandra Domingo, Cristina Solé, Teresa Moliné, Berta Ferrer & Josefina Cortés-Hernández. (2021) Thalidomide Exerts Anti-Inflammatory Effects in Cutaneous Lupus by Inhibiting the IRF4/NF-ҡB and AMPK1/mTOR Pathways. Biomedicines 9:12, pages 1857.
Crossref
Crossref
Cinzia Fionda, Helena Stabile, Rosa Molfetta, Andrea Kosta, Giovanna Peruzzi, Silvia Ruggeri, Alessandra Zingoni, Cristina Capuano, Alessandra Soriani, Rossella Paolini, Angela Gismondi, Marco Cippitelli & Angela Santoni. (2021) Cereblon regulates NK cell cytotoxicity and migration via Rac1 activation. European Journal of Immunology 51:11, pages 2607-2617.
Crossref
Crossref
Isaac Park, Tra Mi Phan & Jing Fang. (2021) Novel Molecular Mechanism of Lenalidomide in Myeloid Malignancies Independent of Deletion of Chromosome 5q. Cancers 13:20, pages 5084.
Crossref
Crossref
Guoqiang Dong, Yu Ding, Shipeng He & Chunquan Sheng. (2021) Molecular Glues for Targeted Protein Degradation: From Serendipity to Rational Discovery. Journal of Medicinal Chemistry 64:15, pages 10606-10620.
Crossref
Crossref
Max Jan, Adam S. Sperling & Benjamin L. Ebert. (2021) Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide. Nature Reviews Clinical Oncology 18:7, pages 401-417.
Crossref
Crossref
Z Liu, F Mi, M Han, M Tian, L Deng, N Meng, J Luo & R Fu. (2021) Bone marrow-derived mesenchymal stem cells inhibit CD8+ T cell immune responses via PD-1/PD-L1 pathway in multiple myeloma. Clinical and Experimental Immunology 205:1, pages 53-62.
Crossref
Crossref
Jiye Liu, Teru Hideshima, Lijie XingSu WangWenrong ZhouMehmet K. Samur, Tomasz Sewastianik, Daisuke OgiyaGang AnShaobing Gao, Li YangTong JiGiada BianchiKenneth WenYu-Tzu Tai, Nikhil MunshiPaul Richardson, Ruben CarrascoYong Cang & Kenneth C. Anderson. (2021) ERK signaling mediates resistance to immunomodulatory drugs in the bone marrow microenvironment. Science Advances 7:23.
Crossref
Crossref
Digna Parmar & Madhavi Apte. (2021) Angiopoietin inhibitors: A review on targeting tumor angiogenesis. European Journal of Pharmacology 899, pages 174021.
Crossref
Crossref
Kitsada Wudhikarn, Leslie Padrnos, Terra Lasho, Betsy LaPlant, Shaji Kumar, Angela Dispenzieri, Martha Lacy, S. Vincent Rajkumar, Morie Gertz, Abhishek A. Mangaonkar, Wilson Gonsalves, Rhett Ketterling, Chang‐Xin Shi, Rafael Fonseca, A. Keith Stewart & Mrinal M. Patnaik. (2021) Clinical correlates and prognostic impact of clonal hematopoiesis in multiple myeloma patients receiving post‐autologous stem cell transplantation lenalidomide maintenance therapy. American Journal of Hematology 96:5.
Crossref
Crossref
Katie Dunphy, Paul Dowling, Despina Bazou & Peter O’Gorman. (2021) Current Methods of Post-Translational Modification Analysis and Their Applications in Blood Cancers. Cancers 13:8, pages 1930.
Crossref
Crossref
Gedefaw Getnet Amare, Birhanu Geta Meharie & Yaschilal Muche Belayneh. (2020) A drug repositioning success: The repositioned therapeutic applications and mechanisms of action of thalidomide. Journal of Oncology Pharmacy Practice 27:3, pages 673-678.
Crossref
Crossref
Catherine H Schein. (2021) Repurposing approved drugs for cancer therapy. British Medical Bulletin 137:1, pages 13-27.
Crossref
Crossref
Anum Qureshi & Ji Hyun Rhee. (2021) Hyponatraemia due to hypothyroidism: a rare side effect from pomalidomide. BMJ Case Reports 14:3, pages e240168.
Crossref
Crossref
Rongrong Li, Bo Zhao, Xianlang Chen, Jieyu Zhang, Zhiying Liu, Xianling Zhu & Deman Han. (2021) Solubility and apparent thermodynamic analysis of pomalidomide in (acetone + ethanol/isopropanol) and (ethyl acetate + ethanol/isopropanol) and its correlation with thermodynamic model. The Journal of Chemical Thermodynamics 154, pages 106345.
Crossref
Crossref
Sara Ovejero & Jerome Moreaux. (2021) Multi-omics tumor profiling technologies to develop precision medicine in multiple myeloma. Exploration of Targeted Anti-tumor Therapy.
Crossref
Crossref
Franco Iodice, Marco Di Mauro, Marco Giuseppe Migliaccio, Angela Iannuzzi, Roberta Pacileo, Martina Caiazza & Augusto Esposito. (2021) Cardiac Amyloidosis Therapy: A Systematic Review. Cardiogenetics 11:1, pages 10-17.
Crossref
Crossref
Marco Cippitelli, Helena Stabile, Andrea Kosta, Sara Petillo, Angela Gismondi, Angela Santoni & Cinzia Fionda. (2021) Role of Aiolos and Ikaros in the Antitumor and Immunomodulatory Activity of IMiDs in Multiple Myeloma: Better to Lose Than to Find Them. International Journal of Molecular Sciences 22:3, pages 1103.
Crossref
Crossref
Kimberley Doucette, Judith Karp & Catherine Lai. (2021) Advances in therapeutic options for newly diagnosed, high-risk AML patients. Therapeutic Advances in Hematology 12, pages 204062072110011.
Crossref
Crossref
Ryosuke Shirasaki, Geoffrey M. Matthews, Sara Gandolfi, Ricardo de Matos Simoes, Dennis L. Buckley, Joseline Raja Vora, Quinlan L. Sievers, Johanna B. Brüggenthies, Olga Dashevsky, Haley Poarch, Huihui Tang, Megan A. Bariteau, Michal Sheffer, Yiguo Hu, Sondra L. Downey-Kopyscinski, Paul J. Hengeveld, Brian J. Glassner, Eugen Dhimolea, Christopher J. Ott, Tinghu Zhang, Nicholas P. Kwiatkowski, Jacob P. Laubach, Robert L. Schlossman, Paul G. Richardson, Aedin C. Culhane, Richard W.J. Groen, Eric S. Fischer, Francisca Vazquez, Aviad Tsherniak, William C. Hahn, Joan Levy, Daniel Auclair, Jonathan D. Licht, Jonathan J. Keats, Lawrence H. Boise, Benjamin L. Ebert, James E. Bradner, Nathanael S. Gray & Constantine S. Mitsiades. (2021) Functional Genomics Identify Distinct and Overlapping Genes Mediating Resistance to Different Classes of Heterobifunctional Degraders of Oncoproteins. Cell Reports 34:1, pages 108532.
Crossref
Crossref
Ioannis Koutsavlis. (2020) Progressive multifocal leukoencephalopathy in multiple myeloma. A literature review and lessons to learn. Annals of Hematology 100:1, pages 1-10.
Crossref
Crossref
Daniel A. Rauch, Sydney L. Olson, John C. Harding, Hemalatha Sundaramoorthi, Youngsoo Kim, Tianyuan Zhou, A. Robert MacLeod, Grant Challen & Lee Ratner. (2020) Interferon regulatory factor 4 as a therapeutic target in adult T-cell leukemia lymphoma. Retrovirology 17:1.
Crossref
Crossref
Julia Martinez-Sanchez, Marta Palomo, Sergi Torramade-Moix, Ana Belen Moreno-Castaño, Montserrat Rovira, Gonzalo Gutiérrez-García, Francesc Fernández-Avilés, Gines Escolar, Olaf Penack, Laura Rosiñol, Enric Carreras & Maribel Diaz-Ricart. (2020) The induction strategies administered in the treatment of multiple myeloma exhibit a deleterious effect on the endothelium. Bone Marrow Transplantation 55:12, pages 2270-2278.
Crossref
Crossref
Sharon Koorse Germans, Ozlem Kulak, Prasad Koduru, Dwight Oliver, Jeffery Gagan, Prapti Patel, Larry D AndersonJrJr, Franklin S Fuda, Weina Chen & Jesse Manuel Jaso. (2020) Lenalidomide-Associated Secondary B-Lymphoblastic Leukemia/Lymphoma—A Unique Entity. American Journal of Clinical Pathology 154:6, pages 816-827.
Crossref
Crossref
Courtney M. Campbell, Avirup Guha, Tamanna Haque, Tomas G. Neilan & Daniel Addison. (2020) Repurposing Immunomodulatory Therapies against Coronavirus Disease 2019 (COVID-19) in the Era of Cardiac Vigilance: A Systematic Review. Journal of Clinical Medicine 9:9, pages 2935.
Crossref
Crossref
Shaunna L. Beedie, Phoebe A. Huang, Emily M. Harris, Jonathan D. Strope, Christopher Mahony, Cindy H. Chau, Neil Vargesson & William D. Figg. (2020) Role of cereblon in angiogenesis and in mediating the antiangiogenic activity of immunomodulatory drugs. The FASEB Journal 34:9, pages 11395-11404.
Crossref
Crossref
Elena Genova, Federica Cavion, Marianna Lucafò, Marco Pelin, Gaetana Lanzi, Stefania Masneri, Rosalba Monica Ferraro, Elisa Maria Fazzi, Simona Orcesi, Giuliana Decorti, Alberto Tommasini, Silvia Giliani & Gabriele Stocco. (2020)
Biomarkers and Precision Therapy for Primary Immunodeficiencies: An
In Vitro
Study Based on Induced Pluripotent Stem Cells From Patients
. Clinical Pharmacology & Therapeutics 108:2, pages 358-367.
Crossref
Crossref
Saeid Kargozar, Francesco Baino, Sepideh Hamzehlou, Michael R. Hamblin & Masoud Mozafari. (2020) Nanotechnology for angiogenesis: opportunities and challenges. Chemical Society Reviews 49:14, pages 5008-5057.
Crossref
Crossref
Joshua D. Hansen, Matthew Correa, Mark A. Nagy, Matt Alexander, Veronique Plantevin, Virginia Grant, Brandon Whitefield, Dehua Huang, Timothy Kercher, Roy Harris, Rama Krishna Narla, Jim Leisten, Yang Tang, Mehran Moghaddam, Katalin Ebinger, Joseph Piccotti, Courtney G. Havens, Brian Cathers, James Carmichael, Thomas Daniel, Rupert Vessey, Lawrence G. Hamann, Katerina Leftheris, Derek Mendy, Frans Baculi, Laurie A. LeBrun, Gody Khambatta & Antonia Lopez-Girona. (2020) Discovery of CRBN E3 Ligase Modulator CC-92480 for the Treatment of Relapsed and Refractory Multiple Myeloma. Journal of Medicinal Chemistry 63:13, pages 6648-6676.
Crossref
Crossref
Agata Kowalczyk, Piotr F.J. Lipiński, Krzysztof Karoń, Joanna E. Rode, Krzysztof Lyczko, Jan Cz Dobrowolski, Mikołaj Donten, Dorota Kaczorek, Joanna Poszytek, Robert Kawęcki, Mieczysław Łapkowski, Anna Malkowska, Ireneusz P. Grudzinski & Anna M. Nowicka. (2020) Enantioselective sensing of (S)-Thalidomide in blood plasma with a chiral naphthalene diimide derivative. Biosensors and Bioelectronics, pages 112446.
Crossref
Crossref
Antonio Giovanni Solimando, Angelo Vacca & Domenico Ribatti. (2020) A Comprehensive Biological and Clinical Perspective Can Drive a Patient-Tailored Approach to Multiple Myeloma: Bridging the Gaps between the Plasma Cell and the Neoplastic Niche. Journal of Oncology 2020, pages 1-16.
Crossref
Crossref
Raymond J. Deshaies. (2020) Multispecific drugs herald a new era of biopharmaceutical innovation. Nature 580:7803, pages 329-338.
Crossref
Crossref
Catherine H. Schein. (2019) Repurposing approved drugs on the pathway to novel therapies. Medicinal Research Reviews 40:2, pages 586-605.
Crossref
Crossref
Vanessa Pinto, Rui Bergantim, Hugo R. Caires, Hugo Seca, José E. Guimarães & M. Helena Vasconcelos. (2020) Multiple Myeloma: Available Therapies and Causes of Drug Resistance. Cancers 12:2, pages 407.
Crossref
Crossref
Aishwarya Krishnamurthy, Saptarshi Bhattacharya, Tejal Lathia, Viny Kantroo, Sanjay Kalra & Deep Dutta. (2020) Anticancer Medications and Sodium Dysmetabolism. European Endocrinology 16:2, pages 122.
Crossref
Crossref
Saptarshi Bhattacharya, Alpesh Goyal, Parjeet Kaur, Randeep Singh & Sanjay Kalra. (2020) Anticancer Drug-induced Thyroid Dysfunction. European Endocrinology 16:1, pages 32.
Crossref
Crossref
Sandra Domingo, Cristina Solé, Teresa Moliné, Berta Ferrer, Josep Ordi-Ros & Josefina Cortés-Hernández. (2020) Efficacy of Thalidomide in Discoid Lupus Erythematosus: Insights into the Molecular Mechanisms. Dermatology 236:5, pages 467-476.
Crossref
Crossref
Eiman Y. Ibrahim & Barbara E. Ehrlich. (2020) Prevention of chemotherapy-induced peripheral neuropathy: A review of recent findings. Critical Reviews in Oncology/Hematology 145, pages 102831.
Crossref
Crossref
Alain Ndayisaba, Kurt Jellinger, Thomas Berger & Gregor K. Wenning. (2019) TNFα inhibitors as targets for protective therapies in MSA: a viewpoint. Journal of Neuroinflammation 16:1.
Crossref
Crossref
Jim H. Hughes, Richard N. Upton, Stephanie E. Reuter, Darlene M. Rozewski, Mitch A. Phelps & David J. R. Foster. (2019) Development of a physiologically based pharmacokinetic model for intravenous lenalidomide in mice. Cancer Chemotherapy and Pharmacology 84:5, pages 1073-1087.
Crossref
Crossref
Alan Corcoran. (2019) Rebooting the Myeloma Treatment Programme. EMJ Hematology, pages 36-43.
Crossref
Crossref
Wataru Onodera, Toru Asahi & Naoya Sawamura. (2019) Positive selection of cereblon modified function including its E3 ubiquitin ligase activity and binding efficiency with AMPK. Molecular Phylogenetics and Evolution 135, pages 78-85.
Crossref
Crossref
Jim H. Hughes, Mitch A. Phelps, Richard N. Upton, Stephanie E. Reuter, Yue Gao, John C. Byrd, Michael R. Grever, Craig C. Hofmeister, Guido Marcucci, William Blum, Kristie A. Blum & David J.R. Foster. (2019) Population pharmacokinetics of lenalidomide in patients with B‐cell malignancies. British Journal of Clinical Pharmacology 85:5, pages 924-934.
Crossref
Crossref
Ligia I. Bastea, Geou-Yarh Liou, Veethika Pandey, Alicia K. Fleming, Christina A. von Roemeling, Heike Doeppler, Zhimin Li, Yushi Qiu, Brandy Edenfield, John A. Copland, Han W. Tun & Peter Storz. (2019) Pomalidomide Alters Pancreatic Macrophage Populations to Generate an Immune-Responsive Environment at Precancerous and Cancerous Lesions. Cancer Research 79:7, pages 1535-1548.
Crossref
Crossref
Chiara Corrado, Viviana Costa, Gianluca Giavaresi, Annalisa Calabrese, Alice Conigliaro & Riccardo Alessandro. (2019) Long Non Coding RNA H19: A New Player in Hypoxia-Induced Multiple Myeloma Cell Dissemination. International Journal of Molecular Sciences 20:4, pages 801.
Crossref
Crossref
Myo Htut. (2019) Immunotherapeutic Approaches for Multiple Myeloma: Where Are We Now?. Current Hematologic Malignancy Reports 14:1, pages 1-10.
Crossref
Crossref
Ota Fuchs. (2019) Treatment of Lymphoid and Myeloid Malignancies by Immunomodulatory Drugs. Cardiovascular & Hematological Disorders-Drug Targets 19:1, pages 51-78.
Crossref
Crossref
Samrat Roy Choudhury & Brian A. Walker. 2019. The DNA, RNA, and Histone Methylomes. The DNA, RNA, and Histone Methylomes
543
572
.
Jie Gu, Sha Song, Huiying Han, Hongxia Xu, Gao Fan, Chen’ao Qian, Yingchun Qiu, Wenqi Zhou, Wenzhuo Zhuang & Bingzong Li. (2018) The BET Bromodomain Inhibitor OTX015 Synergizes with Targeted Agents in Multiple Myeloma. Molecular Pharmaceutics 15:11, pages 5387-5396.
Crossref
Crossref
Alberto Aimo, Gabriele Buda, Marianna Fontana, Andrea Barison, Giuseppe Vergaro, Michele Emdin & Giampaolo Merlini. (2018) Therapies for cardiac light chain amyloidosis: An update. International Journal of Cardiology 271, pages 152-160.
Crossref
Crossref
Peter H Schafer, Ying Ye, Lei Wu, Jolanta Kosek, Garth Ringheim, Zhihong Yang, Liangang Liu, Michael Thomas, Maria Palmisano & Rajesh Chopra. (2018) Cereblon modulator iberdomide induces degradation of the transcription factors Ikaros and Aiolos: immunomodulation in healthy volunteers and relevance to systemic lupus erythematosus. Annals of the Rheumatic Diseases 77:10, pages 1516-1523.
Crossref
Crossref
Gerd Schnorrenberg. 2018. Successful Drug Discovery. Successful Drug Discovery
1
39
.
Jinxu Gao, Adelphe Mfuh, Yuka Amako & Christina M. Woo. (2018) Small Molecule Interactome Mapping by Photoaffinity Labeling Reveals Binding Site Hotspots for the NSAIDs. Journal of the American Chemical Society 140:12, pages 4259-4268.
Crossref
Crossref
Luigia Rao, Kim De Veirman, Donato Giannico, Ilaria Saltarella, Vanessa Desantis, Maria Antonia Frassanito, Antonio Giovanni Solimando, Domenico Ribatti, Marcella Prete, Andreas Harstrick, Ulrike Fiedler, Hendrik De Raeve, Vito Racanelli, Karin Vanderkerken & Angelo Vacca. (2018) Targeting angiogenesis in multiple myeloma by the VEGF and HGF blocking DARPin® protein MP0250: a preclinical study. Oncotarget 9:17, pages 13366-13381.
Crossref
Crossref
Alicia J. Angelbello, Jonathan L. Chen, Jessica L. Childs-Disney, Peiyuan Zhang, Zi-Fu Wang & Matthew D. Disney. (2018) Using Genome Sequence to Enable the Design of Medicines and Chemical Probes. Chemical Reviews 118:4, pages 1599-1663.
Crossref
Crossref
SeungHwan Lee, Jun Gi Hwang, Sang Yeob Park, Hye Jung Lim, Sa-Won Lee, Min-Hyo Seo, JaeWoo Kim & Jang Hee Hong. (2018) Single-Dose Comparative Pharmacokinetics of Two Formulations of Lenalidomide 25 mg in Healthy Subjects: A Randomized Crossover Study. Advances in Therapy 35:2, pages 210-217.
Crossref
Crossref
Gordon Cook, Sonja Zweegman, María-Victoria Mateos, Florence Suzan & Philippe Moreau. (2018) A question of class: Treatment options for patients with relapsed and/or refractory multiple myeloma. Critical Reviews in Oncology/Hematology 121, pages 74-89.
Crossref
Crossref
Monika Engelhardt, Stefanie Ajayi, Heike Reinhardt, Stefan Jürgen Müller, Sandra Maria Dold & Ralph Wäsch. 2018. Small Molecules in Hematology. Small Molecules in Hematology
169
185
.
Sulaiman Haji Ali, K Aljenaee, W A Wan Mahmood & M Hatunic. (2017) Pomalidomide-induced hypothyroidism. Endocrinology, Diabetes & Metabolism Case Reports.
Crossref
Crossref
Elvira Valera, Brian Spencer, Jerel A. Fields, Ivy Trinh, Anthony Adame, Michael Mante, Edward Rockenstein, Paula Desplats & Eliezer Masliah. (2017) Combination of alpha-synuclein immunotherapy with anti-inflammatory treatment in a transgenic mouse model of multiple system atrophy. Acta Neuropathologica Communications 5:1.
Crossref
Crossref
Sheridan M. Hoy. (2017) Pomalidomide: A Review in Relapsed and Refractory Multiple Myeloma. Drugs 77:17, pages 1897-1908.
Crossref
Crossref
David A. Davis, Suraj Mishra, Holda A. Anagho, Ashley I. Aisabor, Prabha Shrestha, Victoria Wang, Yuki Takamatsu, Kenji Maeda, Hiroaki Mitsuya, Jerome B. Zeldis & Robert Yarchoan. (2017) Restoration of immune surface molecules in Kaposi sarcoma-associated herpes virus infected cells by lenalidomide and pomalidomide. Oncotarget 8:31, pages 50342-50358.
Crossref
Crossref
Kimberly Noonan & Kathleen Colson. (2017) Immunomodulatory Agents and Proteasome Inhibitors in the Treatment of Multiple Myeloma. Seminars in Oncology Nursing 33:3, pages 279-291.
Crossref
Crossref
Mattia D’Agostino, Mario Boccadoro & Eric L. Smith. (2017) Novel Immunotherapies for Multiple Myeloma. Current Hematologic Malignancy Reports 12:4, pages 344-357.
Crossref
Crossref
Jianlin Qiao, Yulu Wu, Xiaoqing Wu, Yun Liu, Xiaoqian Li, Wen Ju, Kunming Qi, Depeng Li, Elizabeth E. Gardiner, Robert K. Andrews, Lingyu Zeng & Kailin Xu. (2017)
An absence of platelet activation following thalidomide treatment
in vitro
or
in vivo
. Oncotarget 8:22, pages 35776-35782.
Crossref
Crossref
Athar Khalil, Rachel Tanos, Nehmé El-Hachem, Mazen Kurban, Patrice Bouvagnet, Fadi Bitar & Georges Nemer. (2017) A HAND to TBX5 Explains the Link Between Thalidomide and Cardiac Diseases. Scientific Reports 7:1.
Crossref
Crossref
Fenggen Yan, Xiumei Mo, Junfeng Liu, Siqi Ye, Xing Zeng & Dacan Chen. (2017) Thymic function in the regulation of T cells, and molecular mechanisms underlying the modulation of cytokines and stress signaling. Molecular Medicine Reports 16:5, pages 7175-7184.
Crossref
Crossref
Nicholas Bingham, Antonia Reale & Andrew Spencer. (2017) An Evidence-Based Approach to Myeloma Bone Disease. Current Hematologic Malignancy Reports 12:2, pages 109-118.
Crossref
Crossref
Haifa Kathrin Al-Ali & Alessandro M. Vannucchi. (2016) Managing patients with myelofibrosis and low platelet counts. Annals of Hematology 96:4, pages 537-548.
Crossref
Crossref
Joseph D. Tariman. (2017) Changes in Cancer Treatment. Nursing Clinics of North America 52:1, pages 65-81.
Crossref
Crossref
Belen Lopez-Millan, Rafael Diaz de la Guardia, Heleia Roca-Ho, Carmen M García-Herrero, Jessie R Lavoie, Michael Rosu-Myles, Elena Gonzalez-Rey, Francisco O'Valle, Gabriel Criado, Mario Delgado & Pablo Menendez. (2017) Therapeutic effect of the immunomodulatory drug lenalidomide, but not pomalidomide, in experimental models of rheumatoid arthritis and inflammatory bowel disease. Experimental & Molecular Medicine 49:2, pages e290-e290.
Crossref
Crossref
Mark Rolfe. (2017) The Holy Grail: Solid Tumor Efficacy by Proteasome Inhibition. Cell Chemical Biology 24:2, pages 125-126.
Crossref
Crossref
Nianhang Chen, Simon Zhou & Maria Palmisano. (2016) Clinical Pharmacokinetics and Pharmacodynamics of Lenalidomide. Clinical Pharmacokinetics 56:2, pages 139-152.
Crossref
Crossref
Qinglin Shi & Lijuan Chen. (2017) Cereblon: A Protein Crucial to the Multiple Functions of Immunomodulatory Drugs as well as Cell Metabolism and Disease Generation. Journal of Immunology Research 2017, pages 1-8.
Crossref
Crossref
P. Ettmayer, R. Schnitzer, A. Bergner & H. Nar. 2017. Comprehensive Medicinal Chemistry III. Comprehensive Medicinal Chemistry III
33
63
.
Jing-Ya Wang, Ya-Ni Huang, Chong-Chi Chiu, David Tweedie, Weiming Luo, Chaim G. Pick, Szu-Yi Chou, Yu Luo, Barry J. Hoffer, Nigel H. Greig & Jia-Yi Wang. (2016) Pomalidomide mitigates neuronal loss, neuroinflammation, and behavioral impairments induced by traumatic brain injury in rat. Journal of Neuroinflammation 13:1.
Crossref
Crossref
Jelena Bila, Aleksandra Sretenovic, Jelena Jelicic, Natasa Tosic, Irena Glumac, Marija Dencic Fekete, Darko Antic, Milena Todorovic Balint, Olivera Markovic, Zoran Milojevic, Milica Radojkovic, Goran Trajkovic, Mila Puric, Sonja Pavlovic & Biljana Mihaljevic. (2016) Prognostic Significance of Cereblon Expression in Patients With Multiple Myeloma. Clinical Lymphoma Myeloma and Leukemia 16:11, pages 610-615.
Crossref
Crossref
Rebekah L. Browning, William H. Byrd, Nikhil Gupta, Jeffrey Jones, Xiaokui Mo, Erin Hertlein, Lianbo Yu, Natarajan Muthusamy & John C. Byrd. (2016) Lenalidomide Induces Interleukin-21 Production by T Cells and Enhances IL21-Mediated Cytotoxicity in Chronic Lymphocytic Leukemia B Cells. Cancer Immunology Research 4:8, pages 698-707.
Crossref
Crossref
Hyoung Kyu Kim, Tae Hee Ko, Bayalagmaa Nyamaa, Sung Ryul Lee, Nari Kim, Kyung Soo Ko, Byoung Doo Rhee, Chul-Seung Park, Bernd Nilius & Jin Han. (2016) Cereblon in health and disease. Pflügers Archiv - European Journal of Physiology 468:8, pages 1299-1309.
Crossref
Crossref
Ziyan Zhao, James A. deMayo, Ashley M. West, Marcy J. Balunas & Adam Zweifach. (2016) Development of an Enhanced Phenotypic Screen of Cytotoxic T-Lymphocyte Lytic Granule Exocytosis Suitable for Use with Synthetic Compound and Natural Product Collections. SLAS Discovery 21:6, pages 556-566.
Crossref
Crossref
R Gopalakrishnan, H Matta, B Tolani, T Triche Jr & P M Chaudhary. (2015) Immunomodulatory drugs target IKZF1-IRF4-MYC axis in primary effusion lymphoma in a cereblon-dependent manner and display synergistic cytotoxicity with BRD4 inhibitors. Oncogene 35:14, pages 1797-1810.
Crossref
Crossref
Ayse Pinar Ercetin, Mehmet Ali Ozcan, Safiye Aktas, Faize Yuksel, Serife Medeni Solmaz, Gokmen Omur Sevindik, Abdullah Katgi, Ozden Piskin & Bulent Undar. (2016) Ex vivo evaluation of the effect of regulatory T cells on the anti-tumor activity of bortezomib in multiple myeloma. Experimental Hematology 44:4, pages 223-230.
Crossref
Crossref
Emily Rychak, Derek Mendy, Tao Shi, Yuhong Ning, Jim Leisten, Ling Lu, Karen Miller, Rama K. Narla, Robert Z. Orlowski, Heather K. Raymon, Chad C. Bjorklund, Anjan Thakurta, Anita K. Gandhi, Brian E. Cathers, Rajesh Chopra, Thomas O. Daniel & Antonia Lopez-Girona. (2016) Pomalidomide in combination with dexamethasone results in synergistic anti-tumour responses in pre-clinical models of lenalidomide-resistant multiple myeloma. British Journal of Haematology 172:6, pages 889-901.
Crossref
Crossref
Rossana Maffei, Elisabetta Colaci, Stefania Fiorcari, Silvia Martinelli, Leonardo Potenza, Mario Luppi & Roberto Marasca. (2016) Lenalidomide in chronic lymphocytic leukemia: the present and future in the era of tyrosine kinase inhibitors. Critical Reviews in Oncology/Hematology 97, pages 291-302.
Crossref
Crossref
Zhenqiang He, Richard Alan MitteerJrJr, Yonggao Mou & Yi Fan. 2016. Glioblastoma. Glioblastoma
55
72
.
Thejal Srikumar & Jaya Padmanabhan. 2016. Drug Discovery from Mother Nature. Drug Discovery from Mother Nature
209
228
.
Elvira Valera, Michael Mante, Scott Anderson, Edward Rockenstein & Eliezer Masliah. (2015) Lenalidomide reduces microglial activation and behavioral deficits in a transgenic model of Parkinson’s disease. Journal of Neuroinflammation 12:1.
Crossref
Crossref
Erez Eitan, Emmette R. Hutchison, Nigel H. Greig, David Tweedie, Hasan Celik, Soumita Ghosh, Kenneth W. Fishbein, Richard G. Spencer, Carl Y. Sasaki, Paritosh Ghosh, Soumen Das, Susheela Chigurapati, James Raymick, Sumit Sarkar, Srinivasulu Chigurupati, Sudipta Seal & Mark P. Mattson. (2015) Combination therapy with lenalidomide and nanoceria ameliorates CNS autoimmunity. Experimental Neurology 273, pages 151-160.
Crossref
Crossref
Boel De Paepe & Jana Zschüntzsch. (2015) Scanning for Therapeutic Targets within the Cytokine Network of Idiopathic Inflammatory Myopathies. International Journal of Molecular Sciences 16:8, pages 18683-18713.
Crossref
Crossref
Anna Jonasova, Radka Bokorova, Jaroslav Polak, Martin Vostry, Arnost Kostecka, Hana Hajkova, Radana Neuwirtova, Magda Siskova, Dana Sponerova, Jaroslav Cermak, Dana Mikulenkova, Libor Cervinek, Jana Brezinova, Kyra Michalova & Ota Fuchs. (2015) High level of full-length cereblon mRNA in lower risk myelodysplastic syndrome with isolated 5q deletion is implicated in the efficacy of lenalidomide. European Journal of Haematology 95:1, pages 27-34.
Crossref
Crossref
Maxwell M. KremAjay K. Gopal. (2015) New Targeted Therapies for Indolent B-Cell Malignancies in Older Patients. American Society of Clinical Oncology Educational Book:35, pages e365-e374.
Crossref
Crossref
Marco Rossi, Teresa Calimeri, Pierosandro Tagliaferri & Pierfrancesco Tassone. (2015) Multiple myeloma-related bone disease: state-of-art and next future treatments. International Journal of Hematologic Oncology 4:1, pages 33-47.
Crossref
Crossref
Ethan Toumishey, Angeli Prasad, Greg Dueck, Neil Chua, Daygen Finch, James Johnston, Richard van der Jagt, Doug Stewart, Darrell White, Andrew Belch & Tony Reiman. (2015) Final report of a phase 2 clinical trial of lenalidomide monotherapy for patients with T-cell lymphoma. Cancer 121:5, pages 716-723.
Crossref
Crossref
J??r??my Thalgott, Damien Dos-Santos-Luis & Franck Lebrin. (2015) Pericytes as targets in hereditary hemorrhagic telangiectasia. Frontiers in Genetics 6.
Crossref
Crossref
Yuan Xiao Zhu, Hongwei Yin, Laura A. Bruins, Chang-Xin Shi, Patrick Jedlowski, Meraj Aziz, Chris Sereduk, Klaus Martin Kortuem, Jessica E. Schmidt, Mia Champion, Esteban Braggio & A. Keith Stewart. (2015) RNA interference screening identifies lenalidomide sensitizers in multiple myeloma, including RSK2. Blood 125:3, pages 483-491.
Crossref
Crossref
Hyo Jung KimSung-Soo YoonHyeon Seok EomKihyun KimJin Seok KimJe-Jung LeeSoo-Mee BangChang-Ki MinJoon Seong ParkJae-Hoon Lee. (2015) Use of lenalidomide in the management of relapsed or refractory multiple myeloma: expert recommendations in Korea. Blood Research 50:1, pages 7.
Crossref
Crossref
Chorom Pak, Natalie S. Callander, Edmond W. K. Young, Benjamin TitzKyungMann Kim, Sandeep Saha, Kenny Chng, Fotis Asimakopoulos, David J. Beebe & Shigeki Miyamoto. (2015)
MicroC
3
: an ex vivo microfluidic cis-coculture assay to test chemosensitivity and resistance of patient multiple myeloma cells
. Integrative Biology 7:6, pages 643-654.
Crossref
Crossref
Tsutomu Kobayashi, Junya Kuroda, Shin-ichi Fuchida, Hitomi Kaneko, Hideo Yagi, Hirohiko Shibayama, Hirokazu Tanaka, Satoru Kosugi, Nobuhiko Uoshima, Masayuki Kobayashi, Yoko Adachi, Kensuke Ohta, Kazuyoshi Ishii, Hitoji Uchiyama, Mitsuhiro Matsuda, Eiji Nakatani, Mitsuru Tsudo, Chihiro Shimazaki, Akifumi Takaori-Kondo, Shosaku Nomura, Itaru Matsumura, Masafumi Taniwaki & Yuzuru Kanakura. (2014) Impact of early use of lenalidomide and low-dose dexamethasone on clinical outcomes in patients with relapsed/refractory multiple myeloma. International Journal of Hematology 101:1, pages 37-45.
Crossref
Crossref
B Tan, Y Li, Q Zhao, L Fan, Y Liu, D Wang & X Zhao. (2014) Inhibition of Vav3 could reverse the drug resistance of gastric cancer cells by downregulating JNK signaling pathway. Cancer Gene Therapy 21:12, pages 526-531.
Crossref
Crossref
David Wong, Oliver Winter, Christina Hartig, Svenja Siebels, Martin Szyska, Benjamin Tiburzy, Lingzhang Meng, Upasana Kulkarni, Anke F?hnrich, Kurt Bommert, Ralf Bargou, Claudia Berek, Van Trung Chu, Bjarne Bogen, Franziska Jundt & Rudolf Armin Manz. (2014) Eosinophils and Megakaryocytes Support the Early Growth of Murine MOPC315 Myeloma Cells in Their Bone Marrow Niches. PLoS ONE 9:10, pages e109018.
Crossref
Crossref
HONGYANG WU, CHENCHEN ZHAO, KANGSHENG GU, YANG JIAO, JIQING HAO & GUOPING SUN. (2014) Thalidomide plus chemotherapy exhibit enhanced efficacy in the clinical treatment of T-cell non-Hodgkin’s lymphoma: A prospective study of 46 cases. Molecular and Clinical Oncology 2:5, pages 695-700.
Crossref
Crossref
Kaitlin N. Highsmith, Sheree E. Chen & Sandy Horowitz. (2014) Carfilzomib and Pomalidomide: Recent Advances in the Treatment of Multiple Myeloma. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 34:9, pages 927-940.
Crossref
Crossref
Fabrice Smieliauskas, Chun-Ru Chien, Chan Shen, Daniel M. Geynisman & Ya-Chen Tina Shih. (2014) Cost-Effectiveness Analyses of Targeted Oral Anti-Cancer Drugs: A Systematic Review. PharmacoEconomics 32:7, pages 651-680.
Crossref
Crossref
Albert Oriol. (2014) Pomalidomide in the treatment of multiple myeloma and perspectives in other hematological malignancies. International Journal of Hematologic Oncology 3:3, pages 223-231.
Crossref
Crossref
Kelly Faulk, Lia Gore & Todd Cooper. (2014) Overview of Therapy and Strategies for Optimizing Outcomes in De Novo Pediatric Acute Myeloid Leukemia. Pediatric Drugs 16:3, pages 213-227.
Crossref
Crossref
Francisco J. R. Paumgartten. (2014) Thalidomide and its analogues: comparative clinical efficacy and safety, and cost-effectiveness. Cadernos de Sa?de P?blica 30:4, pages 684-686.
Crossref
Crossref
Shandiz Shahbazi, Cody J. Peer, Mark N. Polizzotto, Thomas S. Uldrick, Jeffrey Roth, Kathleen M. Wyvill, Karen Aleman, Jerome B. Zeldis, Robert Yarchoan & William D. Figg. (2014) A sensitive and robust HPLC assay with fluorescence detection for the quantification of pomalidomide in human plasma for pharmacokinetic analyses. Journal of Pharmaceutical and Biomedical Analysis 92, pages 63-68.
Crossref
Crossref
Lesley J. Scott. (2014) Pomalidomide: A Review of Its Use in Patients with Recurrent Multiple Myeloma. Drugs 74:5, pages 549-562.
Crossref
Crossref
Zeen Tong, Usha Yerramilli, Sekhar Surapaneni & Gondi Kumar. (2014) The interactions of lenalidomide with human uptake and efflux transporters and UDP-glucuronosyltransferase 1A1: lack of potential for drug–drug interactions. Cancer Chemotherapy and Pharmacology 73:4, pages 869-874.
Crossref
Crossref
Norie Murayama, Rinie van Beuningen, Hiroshi Suemizu, Christiane Guguen-Guillouzo, Norio Shibata, Kanako Yajima, Masahiro Utoh, Makiko Shimizu, Christophe Chesné, Masato Nakamura, F. Peter Guengerich, René Houtman & Hiroshi Yamazaki. (2014) Thalidomide Increases Human Hepatic Cytochrome P450 3A Enzymes by Direct Activation of the Pregnane X Receptor. Chemical Research in Toxicology 27:2, pages 304-308.
Crossref
Crossref
Goutam Chowdhury, Norio Shibata, Hiroshi Yamazaki & F. Peter Guengerich. (2013) Human Cytochrome P450 Oxidation of 5-Hydroxythalidomide and Pomalidomide, an Amino Analogue of Thalidomide. Chemical Research in Toxicology 27:1, pages 147-156.
Crossref
Crossref
A. Keith Stewart. (2014) How Thalidomide Works Against Cancer. Science 343:6168, pages 256-257.
Crossref
Crossref
Gang LuRichard E. MiddletonHuahang SunMarkVic NaniongChristopher J. OttConstantine S. MitsiadesKwok-Kin WongJames E. BradnerWilliam G. KaelinJr.Jr.. (2014) The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins. Science 343:6168, pages 305-309.
Crossref
Crossref
Roberto Ria. (2014) Novel agents and new therapeutic approaches for treatment of multiple myeloma. World Journal of Methodology 4:2, pages 73.
Crossref
Crossref
Ahmed M. L. Bedewy & Shereen M. EL-Maghraby. (2014) Do baseline Cereblon gene expression and IL-6 receptor expression determine the response to thalidomide-dexamethasone treatment in Multiple myeloma patients?. European Journal of Haematology 92:1, pages 13-18.
Crossref
Crossref
Roger N. Pearse. (2014) IMiDs: Not for the CRBN weak. Leukemia Research 38:1, pages 21-22.
Crossref
Crossref
Yao Jiang, Jiang Wang, Darlene M. Rozewski, Shamalatha Kolli, Chia-Hsien Wu, Ching-Shih Chen, Xiaoxia Yang, Craig C. Hofmeister, John C. Byrd, Amy J. Johnson & Mitch A. Phelps. (2014) Sensitive liquid chromatography/mass spectrometry methods for quantification of pomalidomide in mouse plasma and brain tissue. Journal of Pharmaceutical and Biomedical Analysis 88, pages 262-268.
Crossref
Crossref
John C. Byrd & Joseph M. Flynn. 2014. Abeloff's Clinical Oncology. Abeloff's Clinical Oncology
1958
1978.e7
.
Kihyun Kim, Seok Jin Kim, Verena Voelter, Cheolwon Suh, Sung-Soo Yoon, Je-Jung Lee, Jae-Yong Kwak, Hun-Mo Ryoo, Yang Soo Kim, Joon Ho Moon, Seong Kyu Park, Sung-Hyun Kim, Yeung-Chul Mun, Jin Seok Kim, Hyeon-Seok Eom, Deog-Yeon Jo, Hyun Jung Jun, Ki-Hwan Kim, Jeong-Ok Lee, Jae Hoon Lee & Chang-Ki Min. (2013) Lenalidomide with dexamethasone treatment for relapsed/refractory myeloma patients in Korea—experience from 110 patients. Annals of Hematology 93:1, pages 113-121.
Crossref
Crossref
Alexandra J. Greenberg, Denise K. Walters, Shaji K. Kumar, S. Vincent Rajkumar & Diane F. Jelinek. (2013) Responsiveness of cytogenetically discrete human myeloma cell lines to lenalidomide: lack of correlation with cereblon and interferon regulatory factor 4 expression levels. European Journal of Haematology 91:6, pages 504-513.
Crossref
Crossref
Martha Q. Lacy & Arleigh R. McCurdy. (2013) Pomalidomide. Blood 122:14, pages 2305-2309.
Crossref
Crossref
A A Chanan-Khan, A Swaika, A Paulus, S K Kumar, J R Mikhael, S V Rajkumar, A Dispenzieri & M Q Lacy. (2013) Pomalidomide: the new immunomodulatory agent for the treatment of multiple myeloma. Blood Cancer Journal 3:9, pages e143-e143.
Crossref
Crossref
Noopur Raje & Sundar JagannathNoopur RajeSundar Jagannath. 2013. Current & Emerging Therapeutics for Multiple Myeloma. Current & Emerging Therapeutics for Multiple Myeloma
2
5
.
Noopur Raje & Sundar Jagannath. 2013. Current & Emerging Therapeutics for Multiple Myeloma. Current & Emerging Therapeutics for Multiple Myeloma.
Christopher S. Hourigan & Judith E. Karp. (2013) Minimal residual disease in acute myeloid leukaemia. Nature Reviews Clinical Oncology 10:8, pages 460-471.
Crossref
Crossref
Peter A Forsberg & Tomer M Mark. (2013) Pomalidomide in the treatment of relapsed multiple myeloma. Future Oncology 9:7, pages 939-948.
Crossref
Crossref
Carsten U. Niemann, Jade Jones & Adrian Wiestner. 2013. Advances in Chronic Lymphocytic Leukemia. Advances in Chronic Lymphocytic Leukemia
259
291
.